| Product Unit Size | Cost | Quantity | Stock |
|---|
CH5424802 is an inhibitor of anaplastic lymphoma kinase (ALK) that displays anticancer chemotherapeutic and anti-metastatic activities against WT and L1196M mutant ALK. This compound is in clinical trials as a potential treatment for various cancers. CH5424802 induces regression of non-small cell lung cancer (NSCLC) cell metastasis in the brain in vivo, increasing survival rates. This compound displays efficacy in subjects resistant to crizotanib.
| Cas No. | 1256580-46-7 |
|---|---|
| Purity | ≥99% |
| Formula | C30H34N4O2 |
| Formula Wt. | 482.62 |
| IUPAC Name | 9-ethyl-6,6-dimethyl-8-(4-morpholin-4-ylpiperidin-1-yl)-11-oxo-5H-benzo[b]carbazole-3-carbonitrile |
| Synonym | CH 5424802, Alectinib |
| Solubility | DMSO 0.5 mg/mL warmed (1.03 mM) Water Insoluble Ethanol Insoluble |
| Appearance | White to off white powder |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Santarpia M, Altavilla G, Rosell R. Alectinib: a selective, next-generation ALK inhibitor for treatment of ALK-rearranged non-small-cell lung cancer. Expert Rev Respir Med. 2015 Feb 5:1-14. [Epub ahead of print]. PMID: 25652176.
Kodama T, Hasegawa M, Takanashi K, et al. Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases. Cancer Chemother Pharmacol. 2014 Nov;74(5):1023-8. PMID: 25205428.
Kodama T, Tsukaguchi T, Yoshida M, et al. Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance. Cancer Lett. 2014 Sep 1;351(2):215-21. PMID: 24887559.
Rossi A, Maione P, Sacco PC, et al. ALK inhibitors and advanced non-small cell lung cancer (review). Int J Oncol. 2014 Aug;45(2):499-508. PMID: 24889366.